Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

The legal challenge carries a risk as well, as it could cupper the development of Enanta's drug – and possibly Pardes' – if Pfizer can prove it was the first to develop a drug candidate ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...

Hedge fund Starboard halved its stake in Pfizer (NYSE:PFE) in the first quarter, amid an activist challenge to the healthcare giant. It also slightly reduced its holding in Tinder-parent Match ...

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their ...

May 14, 2025 Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now Biotech ... would be difficult to implement and face legal challenges. The United States and China on Monday ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...

According to InvestingPro data, the company faces significant financial challenges ... ITIL agreed to cover a transaction fee and Pfizer’s legal expenses. Iterum’s CEO, Corey Fishman ...